Gut Microbiota-Regulated Pharmacokinetics of Berberine and Active Metabolites in Beagle Dogs After Oral Administration.
Gut Microbiota-Regulated Pharmacokinetics of Berberine and Active Metabolites in Beagle Dogs After Oral Administration.
复制标题
DOI:
10.3389/fphar.2018.00214
复制
发表时间:
2018
影响因子:
5.6
通讯作者:
Jiang JD
中科院分区:
文献类型:
--
作者:
Feng R;Zhao ZX;Ma SR;Guo F;Wang Y;Jiang JD
Berberine (BBR) is considered a multi-target drug that has significant advantages. In contrast to its significant pharmacological effects in clinic, the plasma level of BBR is very low. Our previous work revealed that dihydroberberine (dhBBR) could be an absorbable form of BBR in the intestine, and butyrate is an active metabolite that is generated by gut bacteria in rats. In this study, for the first time we describe gut microbiota-regulated pharmacokinetics in beagle dogs after oral administration of BBR by single (50 mg/kg) or multiple doses (50 mg/kg/d) for 7 days. GC-MS, GC, LC-MS/MS, and LC/MSn-IT-TOF were used to detect dhBBR, butyrate and BBR as well as its Phase I and II metabolites, respectively. The results showed that dhBBR was not detected in dog plasma but was excreted in small amounts in the feces of dogs examined on days 3 and 7. Butyrate was generated by gut bacteria and increased by 1.3- and 1.2-fold in plasma or feces, respectively, after 7 days of BBR treatment compared to the levels before treatment. Changes of intestinal bacterial composition were analyzed by 16S rRNA genes analysis. The results presented that dogs treated with BBR for 7 days increased both the abundance of the butyrate- and the nitroreductases- producing bacteria. We also identified chemical structures of the Phase I and II metabolites and analyzed their contents in beagle dogs. Eleven metabolites were detected in plasma and feces after BBR oral administration (50 mg/kg) to dogs, including 8 metabolites of Phase I and III metabolites of Phase II. The pharmacokinetic profile indicated that the concentration of BBR in plasma was low, with a Cmax value of 36.88 ± 23.45 ng/mL. The relative content of glucuronic acid conjugates (M11) was higher than those of other metabolites (M1, M2, M12, and M14) in plasma. BBR was detected in feces, with high excreted amounts on day 3 (2625.04 ± 1726.94 μg/g) and day 7 (2793.43 ± 488.10 μg/g). In summary, this is the first study to describe gut microbiota-regulated pharmacokinetics in beagle dogs after oral administration of BBR, which is beneficial for discovery of drugs with poor absorption but good therapeutic efficacy.
登录
查看更多内容
影响因子:
7.4
作者:
Li Y;Ren G;Wang YX;Kong WJ;Yang P;Wang YM;Li YH;Yi H;Li ZR;Song DQ;Jiang JD
通讯作者:
Jiang JD
影响因子:
9.4
作者:
Schapiro, JM;Gupta, R;Limaye, AP
通讯作者:
Limaye, AP
影响因子:
3.7
作者:
Tan XS;Ma JY;Feng R;Ma C;Chen WJ;Sun YP;Fu J;Huang M;He CY;Shou JW;He WY;Wang Y;Jiang JD
通讯作者:
Jiang JD
DOI:
10.1038/ijo.2015.84
发表时间:
2015-09
期刊:
International journal of obesity (2005)
影响因子:
--
作者:
Byrne CS;Chambers ES;Morrison DJ;Frost G
通讯作者:
Frost G
影响因子:
2.6
作者:
Sandri, Misa;Dal Monego, Simeone;Stefanon, Bruno
通讯作者:
Stefanon, Bruno